Navigation Links
Mindray's DC-3 Color Ultrasound Gains U.S. FDA 510(k) Clearance
Date:6/6/2008

SHENZHEN, China, June 6 /Xinhua-PRNewswire/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced it has received 510(k) clearance from the United States Food and Drug Administration ("FDA") for its DC-3 color ultrasound imaging system. The clearance comes in addition to China State Food and Drug Administration ("SFDA") approval and CE Mark granted earlier this year for the sale of the DC-3 in Chinese and European markets, respectively.

"The compact DC-3 combines outstanding 2D imaging and exceptional color Doppler performance," said Mr. Li Xiting, Mindray's president and co-chief executive officer. "With a superior price-to-performance ratio, we are confident that this versatile product will meet the diverse needs and requirements of hospitals, doctors' offices and veterinary clinics around the world."

The DC-3 color ultrasound imaging system is designed to have extensive applications in abdominal, OB/GYN, endovaginal, cardiac, small parts and pediatric markets. The product is ideally suited for U.S. hospitals, doctors' offices and veterinary clinics seeking to replace black and white ultrasound imaging systems. The DC-3 is tailored to expand Mindray's customer base in low-end markets and complements the company's FDA-approved DC-6 and portable M5 ultrasound imaging systems, which are targeted for middle and high-end markets and received FDA 510(k) clearance in September, 2006 and March, 2008, respectively. The company currently offers over 10 medical imaging products of which five have received FDA 510(k) clearance.

Mindray has to date received FDA 510(k) clearance for a total of 16 products, covering patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems.

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has sales and service offices internationally in Amsterdam, Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .

For investor inquiries please contact:

In China:

Susan Du

Mindray Medical International Limited

Tel: +86-755-2658-2518

Email: Susan.Du@Mindray.com

Justin Knapp

Ogilvy Public Relations Worldwide, Beijing

Tel: +86-10-8520-6556

Email: Justin.Knapp@Ogilvy.com

In the United States:

Jeremy Bridgman

Ogilvy Public Relations Worldwide, New York

Tel: +1-212-880-5363


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wal-Mart Expands $4 Prescription List in Colorado
2. Baxa Corporation Named Finalist for Third Year as a Best Company to Work For in Colorado
3. Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th
4. Family history of colorectal cancer linked with reduced risk of cancer recurrence
5. Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts
6. Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider
7. Sundays AIDS Walk Boston at the Esplanade Gets Tribute from Cyndi Lauper at True Colors Concert Tour Launch Rehearsal
8. USC study finds sex, age and ethnicity assciated with colorectal cancer survival
9. TV Commercials Color Gender Choices for Careers
10. Can pathological techniques help identify primary colorectal signet ring cell carcinoma?
11. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Groth Family ... Pasco and Richland, is initiating a charity drive to support the family of ... recent automobile collision. , On October 29th of this year, Cindy Hendrickson ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... celebrated its 10th anniversary with the grand opening of the Sober College Robert ... event spanned two days, December 2-3, and was attended by an overwhelming amount ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio , founder ... national #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer ... Gives Back initiative, and we’re very pleased with the participation in every ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... grow in 2017-2023. Various reasons for growth of the ... higher incidences of chronic diseases, high recovery cost of ... services. Medical lifting sling refers to an assistive ... mobility. These slings connect to the lift and hold ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
Breaking Medicine Technology: